Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2021 | Updates on BTK inhibitors for CLL at EHA 2021

Andrea Visentin • 4 Jun 2021

EHA 2021

Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib

ALPINE ELEVATE CLL R/R ELEVATE CLL TN

Andrea Visentin, MD, PhD, University of Padua, Padova, Italy, discusses exciting updates on the BTK inhibitors acalabrutinib, zanubrutinib and ibrutinib, which will be presented at the virtual European Hematology Association (EHA) Congress 2021. In particular, Dr Visentin highlights updates on the ELEVATE CLL TN trial (NCT02475681), the ELEVATE CLL R/R trial (NCT02477696) and the ALPINE trial (NCT03734016).

Disclosures

Andrea Visentin, MD, PhD, has participated in consultancy work for Gilead, Italffarmaco, Janssen, and Takeda; is a member of the scientific boards of Janssen, Abbvie, CLS Behring; and has participated in speaker’s bureaus for Janssen, Abbvie, AstraZeneca.

Management of BTK class driven adverse events

Andrea Visentin • 1 Jun 2021

Outcomes of TP53-disrupted CLL patients treated with frontline ibrutinib

Andrea Visentin • 1 Jun 2021

Association between IgA during ibrutinib therapy and infection in CLL

Andrea Visentin • 1 Jun 2021

Predicting risk of CLL evolution to Richter’s syndrome

Andrea Visentin • 9 Dec 2020

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024